ArticleBlood2021
Aspirin and antiplatelet treatments in cancer.
Article in Blood, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 3 syntheses or guidelines pooled it, 115 citations in OpenAlex.
- Prognostic value of the platelet-to-lymphocyte ratio in colorectal cancer patients undergoing chemotherapy: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- The prognostic value of pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with esophageal cancer undergoing immunotherapy: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Prognostic value of platelet to lymphocyte ratio in patients with colorectal cancer undergoing chemotherapy: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Exploring platelet-covered and naked circulating tumor cells - a single-cell transcriptomic perspective.Journal of translational medicine · 2026Article
- Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence.Biomarker research · 2026Review
- Platelet-neutrophil cooperation in cancer: mechanisms of metastatic niche formation and implications for prognostic stratification and therapy.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Risk insights for clinical medication: a Mendelian randomization study of 23 drugs and lung cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- TGFβ enhances platelet-breast-cancer-cell interaction and promotes platelet aggregation.The FEBS journal · 2026Article
- Exploring the toxicity of extracts, fractions, and their bioactive components from raw and roasted sea buckthorn seeds on selected human cells.Frontiers in molecular biosciences · 2026Article
- Investigation of the Intensity of Thrombocytosis as a Potential Prognostic Indicator in Canine Malignant Neoplasms.Veterinary medicine international · 2026Article
- Platelet activation, aspirin, and cancer: From basic science to clinical trials.Pharmacological reviews · 2026Review
- Platelet‑circulating tumor cell crosstalk: A pivotal target in cancer diagnosis and therapy (Review).Oncology reports · 2026Review
- Immune cell changes following chemotherapy in advanced pancreatic cancer with variations based on gender.Scientific reports · 2025Article
- Targeting platelet-tumor cell interactions via thromboxane AExperimental hematology & oncology · 2025Article
- Vorapaxar enhanced mitochondria-associated ferroptosis primes cancer immunotherapy via targeting FOXO1/HMOX1 axis.Cell reports. Medicine · 2025Article
- Coagulation markers as independent predictors of colorectal cancer aggressiveness.BMC gastroenterology · 2025Article
- Unveiling the "Dark Matter" of platelet involvement in tumor microenvironment.Journal of pharmaceutical analysis · 2025Review
- Comparative Prognostic Role of PLR and NLR in Colon Cancer: A Retrospective Analysis of Preoperative Inflammatory Markers.Medicina (Kaunas, Lithuania) · 2025Observational
- Predictive value of inflammatory marker PLR in prostate cancer.BMC urology · 2025Article
- Tumor-infiltrating nerves: unraveling the role of cancer neuroscience in tumorigenesis, disease progression, and emerging therapies.Discover oncology · 2025Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Platelets have been hypothesized to promote certain neoplastic malignancies; however, antiplatelet drugs are still not part of routine pharmacological cancer prevention and treatment protocols. Paracrine interactions between platelets and cancer cells have been implicated in potentiating the dissemination, survival within the circulation, and extravasation of cancer cells at distant sites of metastasis. Signals from platelets have also been suggested to confer epigenetic alterations, including upregulating oncoproteins in circulating tumor cells, and secretion of potent growth factors may play roles in promoting mitogenesis, angiogenesis, and metastatic outgrowth. Thrombocytosis remains a marker of poor prognosis in patients with solid tumors. Experimental data suggest that lowering of platelet count may reduce tumor growth and metastasis. On the basis of the mechanisms by which platelets could contribute to cancer growth and metastasis, it is conceivable that drugs reducing platelet count or platelet activation might attenuate cancer progression and improve outcomes. We will review select pharmacological approaches that inhibit platelets and may affect cancer development and propagation. We begin by presenting an overview of clinical cancer prevention and outcome studies with low-dose aspirin. We then review current nonclinical development of drugs targeted to platelet binding, activation, and count as potential mitigating agents in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.